Theralase Technologies Inc. (CVE:TLT – Get Free Report) shares rose 3.8% on Tuesday . The stock traded as high as C$0.27 and last traded at C$0.27. 43,002 shares traded hands during trading, a decline of 82% from the average session volume of 232,504 shares. The stock had previously closed at C$0.26.
Theralase Technologies Stock Performance
The firm has a market cap of C$79.83 million, a price-to-earnings ratio of -19.29 and a beta of -0.57. The firm’s 50 day moving average is C$0.25 and its 200-day moving average is C$0.27. The company has a debt-to-equity ratio of 22.13, a quick ratio of 3.40 and a current ratio of 1.37.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
See Also
- Five stocks we like better than Theralase Technologies
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
